---
title: "Werewolf Therapeutics | 8-K: FY2026 Q1 EPS Beats Estimate at USD -0.28"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285612028.md"
datetime: "2026-05-07T20:26:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285612028.md)
  - [en](https://longbridge.com/en/news/285612028.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285612028.md)
---

# Werewolf Therapeutics | 8-K: FY2026 Q1 EPS Beats Estimate at USD -0.28

EPS: As of FY2026 Q1, the actual value is USD -0.28, beating the estimate of USD -0.295.

Werewolf Therapeutics, Inc. issued a press release on May 7, 2026, announcing its financial results for the quarter ended March 31, 2026 . However, the provided Form 8-K document does not detail specific financial results, such as revenue figures, net income, gross margin, operating profit, operating costs, or cash flow data, as these are stated to be furnished as Exhibit 99.1 . The document includes a general “Cautionary Note Regarding Forward-Looking Statements” which discusses future expectations, plans, prospects, strategy, potential strategic partnerships, projected cash runway, and timelines for product development . This section serves as a broad disclaimer and does not offer specific financial or operational guidance or outlook for future periods .

### Related Stocks

- [HOWL.US](https://longbridge.com/en/quote/HOWL.US.md)

## Related News & Research

- [Key facts: Allogene ends Overland license; ALPHA3 58.3% MRD‑negativity](https://longbridge.com/en/news/286380061.md)
- [Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)](https://longbridge.com/en/news/286408124.md)
- [Karyopharm (KPTI) Leans on SENTRY in Pivotal Call](https://longbridge.com/en/news/287005767.md)
- [RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)](https://longbridge.com/en/news/286559865.md)
- [Larimar Shareholders Approve Governance and Capital Structure Changes](https://longbridge.com/en/news/286968564.md)